Critical Updates in Kidney, Prostate, and Bladder Cancer from ASCO 2023 with Dr. Toni Choueiri

Discussing GU (Genitourinary) Cancer ASCO 2023 Highlights, focusing on practice changing studies with Dr. Toni Choueiri, Director, Lank Center for Genitourinary Oncology and Professor of Medicine at Harvard Medicine School - Dana-Farber Cancer Institute.

Covering four important studies:
- TALAPRO-2: Ph3 study of talazoparib + enzalutamide vs placebo + enzalutamide as first-line (1L) treatment for mCRPC with homologous recombination repair (HRR) gene alterations
- CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab vs sunitinib in pts with advanced renal cell carcinoma
- CONTACT-03: efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior checkpoint inhibitor in metastatic renal cell carcinoma
- THOR: Erdafitinib vs chemo in pts with advanced or metastatic urothelial cancer with select FGFR alteration

#asco #2023 #genitourinary #cancer #drtonichoueiri

Website: http://www.oncbrothers.com/
Twitter:   / oncbrothers  

Contact us at [email protected]